PAION reports positive results of its short acting anaesthetic/sedative Remimazolam (CNS 7056) in a Phase IIb study
PAION expands Desmoteplase agreement with Lundbeck
PAION AG enters into an equity facility agreement for EUR 15 million
Some of them are essential and required for running the website. Others improve your user experience and may be activated or deactivated at your discretion.